170 related articles for article (PubMed ID: 12920090)
1. BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland.
Ikonen T; Matikainen MP; Syrjäkoski K; Mononen N; Koivisto PA; Rökman A; Seppälä EH; Kallioniemi OP; Tammela TL; Schleutker J
J Med Genet; 2003 Aug; 40(8):e98. PubMed ID: 12920090
[No Abstract] [Full Text] [Related]
2. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
3. Clinical management of BRCA1 and BRCA2 mutation carriers.
Domchek SM; Armstrong K; Weber BL
Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
[No Abstract] [Full Text] [Related]
4. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
Ibrahim M; Yadav S; Ogunleye F; Zakalik D
BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
[TBL] [Abstract][Full Text] [Related]
5. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
Meyer P; Voigtlaender T; Bartram CR; Klaes R
Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk assessment at the atomic level.
Monteiro AN; Couch FJ
Cancer Res; 2006 Feb; 66(4):1897-9. PubMed ID: 16488985
[TBL] [Abstract][Full Text] [Related]
7. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
Domchek SM; Rebbeck TR
LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing.
Diez O; Gutiérrez-Enríquez S; Balmaña J
Fam Cancer; 2010 Jun; 9(2):187-91. PubMed ID: 19941167
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 have a limited role in familial prostate cancer.
Sinclair CS; Berry R; Schaid D; Thibodeau SN; Couch FJ
Cancer Res; 2000 Mar; 60(5):1371-5. PubMed ID: 10728701
[TBL] [Abstract][Full Text] [Related]
10. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/2 mutation analysis in male breast cancer families from North West England.
Evans DG; Bulman M; Young K; Howard E; Bayliss S; Wallace A; Lalloo F
Fam Cancer; 2008; 7(2):113-7. PubMed ID: 17636422
[TBL] [Abstract][Full Text] [Related]
12. Comment on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study'.
Paradiso AV; Digennaro M; Sambiasi D
Br J Cancer; 2016 Aug; 115(5):e3. PubMed ID: 27459695
[No Abstract] [Full Text] [Related]
13. Comment on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study'.
Friedenson B
Br J Cancer; 2016 Aug; 115(5):e2. PubMed ID: 27459694
[No Abstract] [Full Text] [Related]
14. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes.
Zhang L; Fleischut MH; Kohut K; Spencer S; Wong K; Stadler ZK; Kauff ND; Offit K; Robson ME
Clin Genet; 2011 Jul; 80(1):97-8. PubMed ID: 21649643
[No Abstract] [Full Text] [Related]
16. Association of Genomic Domains in
Patel VL; Busch EL; Friebel TM; Cronin A; Leslie G; McGuffog L; Adlard J; Agata S; Agnarsson BA; Ahmed M; Aittomäki K; Alducci E; Andrulis IL; Arason A; Arnold N; Artioli G; Arver B; Auber B; Azzollini J; Balmaña J; Barkardottir RB; Barnes DR; Barroso A; Barrowdale D; Belotti M; Benitez J; Bertelsen B; Blok MJ; Bodrogi I; Bonadona V; Bonanni B; Bondavalli D; Boonen SE; Borde J; Borg A; Bradbury AR; Brady A; Brewer C; Brunet J; Buecher B; Buys SS; Cabezas-Camarero S; Caldés T; Caliebe A; Caligo MA; Calvello M; Campbell IG; Carnevali I; Carrasco E; Chan TL; Chu ATW; Chung WK; Claes KBM; Collaborators GS; Collaborators E; Cook J; Cortesi L; Couch FJ; Daly MB; Damante G; Darder E; Davidson R; de la Hoya M; Puppa LD; Dennis J; Díez O; Ding YC; Ditsch N; Domchek SM; Donaldson A; Dworniczak B; Easton DF; Eccles DM; Eeles RA; Ehrencrona H; Ejlertsen B; Engel C; Evans DG; Faivre L; Faust U; Feliubadaló L; Foretova L; Fostira F; Fountzilas G; Frost D; García-Barberán V; Garre P; Gauthier-Villars M; Géczi L; Gehrig A; Gerdes AM; Gesta P; Giannini G; Glendon G; Godwin AK; Goldgar DE; Greene MH; Gutierrez-Barrera AM; Hahnen E; Hamann U; Hauke J; Herold N; Hogervorst FBL; Honisch E; Hopper JL; Hulick PJ; Investigators K; Investigators H; Izatt L; Jager A; James P; Janavicius R; Jensen UB; Jensen TD; Johannsson OT; John EM; Joseph V; Kang E; Kast K; Kiiski JI; Kim SW; Kim Z; Ko KP; Konstantopoulou I; Kramer G; Krogh L; Kruse TA; Kwong A; Larsen M; Lasset C; Lautrup C; Lazaro C; Lee J; Lee JW; Lee MH; Lemke J; Lesueur F; Liljegren A; Lindblom A; Llovet P; Lopez-Fernández A; Lopez-Perolio I; Lorca V; Loud JT; Ma ESK; Mai PL; Manoukian S; Mari V; Martin L; Matricardi L; Mebirouk N; Medici V; Meijers-Heijboer HEJ; Meindl A; Mensenkamp AR; Miller C; Gomes DM; Montagna M; Mooij TM; Moserle L; Mouret-Fourme E; Mulligan AM; Nathanson KL; Navratilova M; Nevanlinna H; Niederacher D; Nielsen FCC; Nikitina-Zake L; Offit K; Olah E; Olopade OI; Ong KR; Osorio A; Ott CE; Palli D; Park SK; Parsons MT; Pedersen IS; Peissel B; Peixoto A; Pérez-Segura P; Peterlongo P; Petersen AH; Porteous ME; Pujana MA; Radice P; Ramser J; Rantala J; Rashid MU; Rhiem K; Rizzolo P; Robson ME; Rookus MA; Rossing CM; Ruddy KJ; Santos C; Saule C; Scarpitta R; Schmutzler RK; Schuster H; Senter L; Seynaeve CM; Shah PD; Sharma P; Shin VY; Silvestri V; Simard J; Singer CF; Skytte AB; Snape K; Solano AR; Soucy P; Southey MC; Spurdle AB; Steele L; Steinemann D; Stoppa-Lyonnet D; Stradella A; Sunde L; Sutter C; Tan YY; Teixeira MR; Teo SH; Thomassen M; Tibiletti MG; Tischkowitz M; Tognazzo S; Toland AE; Tommasi S; Torres D; Toss A; Trainer AH; Tung N; van Asperen CJ; van der Baan FH; van der Kolk LE; van der Luijt RB; van Hest LP; Varesco L; Varon-Mateeva R; Viel A; Vierstraete J; Villa R; von Wachenfeldt A; Wagner P; Wang-Gohrke S; Wappenschmidt B; Weitzel JN; Wieme G; Yadav S; Yannoukakos D; Yoon SY; Zanzottera C; Zorn KK; D'Amico AV; Freedman ML; Pomerantz MM; Chenevix-Trench G; Antoniou AC; Neuhausen SL; Ottini L; Nielsen HR; Rebbeck TR
Cancer Res; 2020 Feb; 80(3):624-638. PubMed ID: 31723001
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
18. Response to 'Comments on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study''.
Narod SA
Br J Cancer; 2016 Aug; 115(5):e4. PubMed ID: 27459693
[No Abstract] [Full Text] [Related]
19. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
20. Mutations in BRCA1 and BRCA2 and predisposition to prostate cancer.
Tischkowitz M; Eeles R;
Lancet; 2003 Jul; 362(9377):80; author reply 80. PubMed ID: 12853213
[No Abstract] [Full Text] [Related]
[Next] [New Search]
